Clinical Trials Logo

Refractory Colorectal Carcinoma clinical trials

View clinical trials related to Refractory Colorectal Carcinoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03576963 Withdrawn - Clinical trials for Colorectal Adenocarcinoma

Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer

Start date: January 30, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This phase Ib/II trial studies the side effects and best dose of guadecitabine when given together with nivolumab and to see how well they work in treating participants with colorectal cancer that does not respond to treatment and has spread to other places in the body. Drugs used in chemotherapy, such as guadecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving guadecitabine and nivolumab may work better in treating participants with colorectal cancer.